Drugs / LY2874455
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03125239 | Aug 2017 → Jun 2020 | acute myeloid leukemia | Jacqueline Garcia, MD | Completed | No outcome recorded |
| Phase 1 | NCT01212107 | Dec 2010 → Aug 2014 | cancer of unknown primary site | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2874455 | “We report here a phase 1 study of LY2874455, a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor.” PMID 28589492 ↗ Aug 2017 |
| Action | Inhibit | “a potent oral selective pan-fibroblast growth factor receptor (FGFR) inhibitor.” PMID 28589492 ↗ Aug 2017 |
| Modality | Small molecule | — CHEMBL3828009 ↗ |
| Route | Oral | “LY2874455 administered orally.” NCT01212107 ↗ |